Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial
Authors:
Open Access
- 30 November 2021
- journal article
- research article
- Published by Springer Nature in Hepatology International
- Vol. 15 (6) , 1402-1412
Abstract
Background & aims: Immunotherapy with hepatitis B virus (HBV)-specific TCR redirected T (HBV-TCR-T) cells in HBV-related hepatocellular carcinoma (HBV-HCC) patients after liver transplantation was reported to be safe and had potential therapeutic efficacy. We aim to investigate the safety of HBV-TCR-T-cell immunotherapy in advanced HBV-HCC patients who had not met the criteria for liver transplantation. Methods: We enrolled eight patients with advanced HBV-HCC and adoptively transferred short-lived autologous T cells expressing HBV-specific TCR to perform an open-label, phase 1 dose-escalation study (NCT03899415). The primary endpoint was to evaluate the safety of HBV-TCR-T-cell therapy according to National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03) during the dose-escalation process. The secondary endpoint was to assess the efficacy of HBV-TCR-T-cell therapy by evaluating the anti-tumor responses using RECIST criteria (version 1.1) and the overall survival. Results: Adverse events were observed in two participants among the 8 patients enrolled. Only one patient experienced a Grade 3 liver-related adverse event after receiving a dose of 1 × 105 HBV-TCR-T cells/kg, then normalized without interventions with immunosuppressive agents. Among the patients, one achieved a partial response lasting for 27.7 months. Importantly, most of the patients exhibited a reduction or stabilization of circulating HBsAg and HBV DNA levels after HBV-TCR-T-cell infusion, indicating the on-target effects. Conclusions: The adoptive transfer of HBV-TCR-T cells into advanced HBV-HCC patients were generally safe and well-tolerated. Observations of clinical efficacy support the continued development and eventual application of this treatment strategy in patients with advanced HBV-related HCC. Clinical trials registration: This study was registered at ClinicalTrials.gov (NCT03899415).Keywords
Funding Information
- National Science and Technology Major Projects (2018ZX10301202)
- Innovative Research Team in the National Natural Science Foundation of China (81721002)
This publication has 27 references indexed in Scilit:
- Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular CarcinomaGastroenterology, 2015
- Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patientJournal of Hepatology, 2015
- The global burden of liver disease: The major impact of ChinaHepatology, 2014
- Acute hepatitis B infection associated with drug-resistant hepatitis B virusJournal of Clinical Virology, 2010
- Safety Analysis of Ex Vivo -Expanded NK and NK-Like T Cells Administered to Cancer Patients: a Phase I Clinical StudyImmunotherapy, 2009
- Dynamic decrease in PD-1 expression correlates with HBV-specific memory CD8 T-cell development in acute self-limited hepatitis B patientsJournal of Hepatology, 2009
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Twenty-year trends of primary liver cancer incidence rates in an urban Chinese populationEuropean Journal Of Cancer Prevention, 2003